CL2021001461A1 - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
CL2021001461A1
CL2021001461A1 CL2021001461A CL2021001461A CL2021001461A1 CL 2021001461 A1 CL2021001461 A1 CL 2021001461A1 CL 2021001461 A CL2021001461 A CL 2021001461A CL 2021001461 A CL2021001461 A CL 2021001461A CL 2021001461 A1 CL2021001461 A1 CL 2021001461A1
Authority
CL
Chile
Prior art keywords
trex1
modulators
compositions
treating
compounds
Prior art date
Application number
CL2021001461A
Other languages
English (en)
Inventor
Victor S Gehling
Anna Gardberg
Avinash Khanna
Julian R Levell
Jonathan E Wilson
Kennedy Taveras
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CL2021001461A1 publication Critical patent/CL2021001461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Se proporcionan compuestos de la Fórmula (I): y sales farmacéuticamente aceptables y composiciones de estos que son útiles para tratar una variedad de afecciones asociadas con TREX1.
CL2021001461A 2018-12-06 2021-06-03 Moduladores de trex1 CL2021001461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776031P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
CL2021001461A1 true CL2021001461A1 (es) 2021-12-17

Family

ID=69024702

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001461A CL2021001461A1 (es) 2018-12-06 2021-06-03 Moduladores de trex1

Country Status (28)

Country Link
US (1) US20220017502A1 (es)
EP (1) EP3891145B1 (es)
JP (1) JP7471297B2 (es)
KR (1) KR20210102310A (es)
CN (1) CN113396149A (es)
AU (1) AU2019395005A1 (es)
BR (1) BR112021010919A2 (es)
CA (1) CA3122093A1 (es)
CL (1) CL2021001461A1 (es)
CO (1) CO2021008816A2 (es)
CY (1) CY1126082T1 (es)
DK (1) DK3891145T3 (es)
EA (1) EA202191519A1 (es)
ES (1) ES2949999T3 (es)
FI (1) FI3891145T3 (es)
HR (1) HRP20230701T1 (es)
HU (1) HUE062866T2 (es)
IL (1) IL283672A (es)
LT (1) LT3891145T (es)
MA (1) MA54386B1 (es)
MX (1) MX2021006695A (es)
PE (1) PE20212070A1 (es)
PL (1) PL3891145T3 (es)
PT (1) PT3891145T (es)
RS (1) RS64336B1 (es)
SG (1) SG11202105772SA (es)
SI (1) SI3891145T1 (es)
WO (1) WO2020118133A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1
US20230278957A1 (en) * 2020-08-04 2023-09-07 Wake Forest University Health Sciences Trex1 inhibitors and uses thereof
JP2024517715A (ja) * 2021-04-26 2024-04-23 コンステレーション・ファーマシューティカルズ・インコーポレイテッド Ｔｒｅｘ１のモジュレーター
BR112023022917A2 (pt) * 2021-05-05 2024-01-23 Constellation Pharmaceuticals Inc Moduladores de trex1
WO2023137030A1 (en) * 2022-01-11 2023-07-20 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152209A1 (en) * 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
US20110124666A1 (en) * 2008-06-02 2011-05-26 Janssen Pharmaceutica NV a corporation 3,4-dihydropyrimidine trpa1 antagonists
CA2774903A1 (en) * 2009-10-02 2011-04-07 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
WO2011107494A1 (de) * 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR085436A1 (es) * 2011-03-17 2013-10-02 Bristol Myers Squibb Co Derivados de pirrolopiridazina inhibidores de jak3, composiciones farmaceuticas que los contienen y su uso para tratar enfermedades inflamatorias y autoinmunes

Also Published As

Publication number Publication date
MX2021006695A (es) 2021-09-23
SG11202105772SA (en) 2021-06-29
PL3891145T3 (pl) 2023-08-07
PE20212070A1 (es) 2021-10-26
MA54386A (fr) 2021-10-13
DK3891145T3 (da) 2023-07-24
JP7471297B2 (ja) 2024-04-19
BR112021010919A2 (pt) 2021-08-24
CA3122093A1 (en) 2020-06-11
ES2949999T3 (es) 2023-10-04
CY1126082T1 (el) 2023-11-15
CO2021008816A2 (es) 2021-07-19
JP2022510431A (ja) 2022-01-26
IL283672A (en) 2021-07-29
MA54386B1 (fr) 2023-08-31
EA202191519A1 (ru) 2021-10-27
FI3891145T3 (fi) 2023-07-18
PT3891145T (pt) 2023-07-18
EP3891145A1 (en) 2021-10-13
WO2020118133A1 (en) 2020-06-11
CN113396149A (zh) 2021-09-14
LT3891145T (lt) 2023-08-10
HUE062866T2 (hu) 2023-12-28
EP3891145B1 (en) 2023-04-12
KR20210102310A (ko) 2021-08-19
AU2019395005A1 (en) 2021-06-17
SI3891145T1 (sl) 2023-11-30
HRP20230701T1 (hr) 2023-10-13
US20220017502A1 (en) 2022-01-20
RS64336B1 (sr) 2023-08-31

Similar Documents

Publication Publication Date Title
CL2021001461A1 (es) Moduladores de trex1
CO2017010583A2 (es) Compuestos de pirazol y método para elaborar y usar los compuestos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY37073A (es) Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
NI202100018A (es) Moduladores de la expresión de pnpla3
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
UY36204A (es) Derivados de insoindolina.
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
UY37941A (es) Derivados de bencimidazol y sus usos
CL2018001067A1 (es) Compuesto piranodipiridínico.
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
ECSP23088732A (es) Moduladores de trex1